CIK 0001347178
- Accelerated filer
Vanda Pharmaceuticals Inc.
Sign in to watch- Ticker
- VNDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 030491827
- Phone
- +1 202-734-3400
- Business address
- 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC, 20037
- Open-market buys, last 90 days
- $38,094
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$38,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-24 | Wijkstrom Joakim SVP, Chief Marketing Officer | Grant or award | +25,800 | 82,090 | ||
| 2021-02-24 | Wijkstrom Joakim SVP, Chief Marketing Officer | Grant or award · Employee Stock Option (Right to Buy) | +61,200 | 61,200 | ||
| 2021-02-24 | Polymeropoulos Mihael Hristos President and CEO | Grant or award | +115,000 | 1,418,747 | ||
| 2021-02-24 | Polymeropoulos Mihael Hristos President and CEO | Grant or award · Employee Stock Option (Right to Buy) | +275,000 | 275,000 | ||
| 2021-02-24 | Moran Kevin Patrick SVP, CFO & Treasurer | Grant or award | +32,700 | 110,797 | ||
| 2021-02-24 | Moran Kevin Patrick SVP, CFO & Treasurer | Grant or award · Employee Stock Option (Right to Buy) | +77,500 | 77,500 | ||
| 2021-02-24 | Jones Aranthan II Chief Corp. Affairs Officer | Grant or award | +25,800 | 101,287 | ||
| 2021-02-24 | Jones Aranthan II Chief Corp. Affairs Officer | Option exercise | +22,499 | $12.27 | $276K | 123,786 |
| 2021-02-24 | Jones Aranthan II Chief Corp. Affairs Officer | Sale | −22,986 | $20.01 | $460K | 100,800 |
| 2021-02-24 | Jones Aranthan II Chief Corp. Affairs Officer | Grant or award · Employee Stock Option (Right to Buy) | +61,200 | 61,200 | ||
| 2021-02-24 | Jones Aranthan II Chief Corp. Affairs Officer | Option exercise · Employee Stock Option (Right to Buy) | −22,499 | 37,501 | ||
| 2021-02-24 | Birznieks Gunther SVP, Business Development | Grant or award | +32,700 | 192,173 | ||
| 2021-02-24 | Birznieks Gunther SVP, Business Development | Grant or award · Employee Stock Option (Right to Buy) | +77,500 | 77,500 | ||
| 2021-02-16 | Watkins Thomas Director | Option exercise | +15,000 | $7.11 | $107K | 55,323 |
| 2021-02-16 | Watkins Thomas Director | Sale | −5,818 | $18.54 | $108K | 49,505 |
| 2021-02-16 | Watkins Thomas Director | Option exercise · Stock Option (Right to Buy) | −15,000 | 0 | ||
| 2021-02-16 | DUGAN RICHARD W Director | Option exercise | +15,000 | $7.11 | $107K | 60,641 |
| 2021-02-16 | DUGAN RICHARD W Director | Sale | −5,754 | $18.54 | $107K | 54,887 |
| 2021-02-16 | DUGAN RICHARD W Director | Option exercise · Stock Option (Right to Buy) | −15,000 | 0 | ||
| 2020-12-15 | Polymeropoulos Mihael Hristos President and CEO | Option exercise | +46,663 | $8.75 | $408K | 1,342,897 |
Page 12 of 20 · 387 trades